CureVac is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company developing medicines based on messenger ribonucleic acid (mRNA). Co.'s product portfolio includes clinical and preclinical candidates in prophylactic vaccines, oncology and molecular therapy. In prophylactic vaccines, Co. is developing its mRNA vaccine candidate, CV2CoV against coronavirus (SARS-CoV-2) in collaboration with GlaxoSmithKline Biologicals SA. CV2CoV is a representative of its COVID-19 vaccine program. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles.